Paul Frohna, MD, PhD

An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.

Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.

An expert lung doctor covers the main adverse events associated with antifibrotic agents and why it is necessary to develop newer pharmacotherapies to treat idiopathic and progressive pulmonary fibrosis.

Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.

An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.

Dr. Paul Frohna discusses the importance of non-pharmacological modalities, as well as utilizing multidisciplinary care, for patients with idiopathic and progressive pulmonary fibrosis.